Vanda Pharmaceuticals | VNDA - Current Assets


Vanda Pharmaceuticals reported $347.26M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Akebia Therapeutics USD 220.78M 8.77M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.71B 72.59M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 7.34B 1.53B Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 33.21B 1.68B Sep/2026
Takeda JPY 3T 153.11B Sep/2026
Teva Pharmaceutical Industries USD 14.6B 842M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Veracyte USD 467.88M 106.9M Sep/2026